Exelixis (EXEL)

The company’s commercial base is built around Cabometyx, which competes in large oncology markets where treatment decisions are shaped by clinical data, physician experience, and evolving combinations with immunotherapies. Exelixis also collaborates with larger pharmaceutical companies to broaden the reach of its products. One example is Cotellic, a melanoma therapy developed with Roche that is used as part of a targeted treatment regimen.

Beyond its marketed medicines, Exelixis invests in a pipeline of oncology candidates designed to extend its presence beyond cabozantinib. Its research strategy includes internally discovered compounds, antibody-drug conjugates, and development partnerships intended to create new treatment options across solid tumours. As a listed biopharmaceutical company, Exelixis is influenced by clinical trial results, regulatory decisions, patent protection, competition from other cancer drug developers, and the commercial performance of its approved therapies.

Exelixis stands out as a mid-sized oncology specialist with an established revenue-generating franchise, rather than a purely clinical-stage biotech. Its investment case is closely tied to the durability of cabozantinib sales and the company’s ability to convert research and development spending into additional approved cancer medicines.